| Primary |
| Hyperphosphataemia |
50.0% |
| Renal Failure |
50.0% |
|
| Product Name Confusion |
33.3% |
| Unresponsive To Stimuli |
33.3% |
| Vomiting |
33.3% |
|
| Secondary |
| Peritoneal Dialysis |
25.0% |
| Drug Use For Unknown Indication |
16.7% |
| Blood Calcium Abnormal |
8.3% |
| Blood Phosphorus Increased |
8.3% |
| Constipation |
8.3% |
| Hyperparathyroidism |
8.3% |
| Hyperphosphataemia |
8.3% |
| Product Used For Unknown Indication |
8.3% |
| Renal Disorder |
8.3% |
|
| Diarrhoea |
14.3% |
| Drug Hypersensitivity |
14.3% |
| Hypercalcaemia |
14.3% |
| Muscular Weakness |
14.3% |
| Renal Impairment |
14.3% |
| Respiratory Paralysis |
14.3% |
| Vomiting |
14.3% |
|
| Concomitant |
| Drug Use For Unknown Indication |
39.4% |
| Product Used For Unknown Indication |
26.1% |
| Nuclear Magnetic Resonance Imaging |
10.0% |
| Angiogram |
3.1% |
| Peritoneal Dialysis |
2.7% |
| Nuclear Magnetic Resonance Imaging Brain |
2.5% |
| Hypertension |
2.1% |
| Pain |
1.5% |
| Dialysis |
1.4% |
| Renal Failure Chronic |
1.4% |
| Prophylaxis |
1.3% |
| Haemodialysis |
1.1% |
| Thrombosis Prophylaxis |
1.1% |
| Diabetes Mellitus |
1.1% |
| Nuclear Magnetic Resonance Imaging Abdominal |
1.1% |
| Anaemia |
1.1% |
| Hyperparathyroidism Secondary |
0.9% |
| Imaging Procedure |
0.8% |
| Fistulogram |
0.7% |
| Multiple Myeloma |
0.6% |
|
| Vomiting |
21.8% |
| Skin Tightness |
12.5% |
| Nephrogenic Systemic Fibrosis |
7.7% |
| Therapeutic Response Decreased |
7.1% |
| Unresponsive To Stimuli |
6.0% |
| Peritonitis Bacterial |
4.7% |
| Nausea |
4.1% |
| Renal Failure Chronic |
3.4% |
| Weight Decreased |
3.4% |
| Skin Induration |
3.1% |
| Myocardial Infarction |
2.9% |
| Pain |
2.9% |
| Sepsis |
2.7% |
| Skin Ulcer |
2.7% |
| Hypotension |
2.6% |
| Renal Failure |
2.6% |
| Urinary Tract Infection |
2.6% |
| Peritonitis |
2.4% |
| Subcutaneous Nodule |
2.4% |
| Thrombocytopenia |
2.4% |
|
